Good morning to you all. Please find enclosed a summary of the breaking small-cap and micro-cap financial news we highlighted on AGORACOM Small Cap TV this morning. It’s March 8th , 2012, and we’ve found 6 great press releases to report on at the open. Another great day for small-cap and micro-cap financial news. To watch the show live every morning at 9:30 AM, visit our front page.

Premier Power Signs $27.6M Contract With Shanghai Chaori for U.S. Solar Plants

Premier Power Renewable Energy, Inc. (OTCBB:PPRW), a global leader in the development and construction of solar power plants, today announced the company has finalized a $27.6 million agreement with Chaori Solar USA, an investment-focused subsidiary of Shanghai Chaori Solar Energy Science & Technology Co., to build high-performance, utility-scale solar power plants in the United States. Construction is scheduled to begin in the first quarter of 2012.

Under the agreement, Premier Power will perform engineering, procurement and construction (EPC) services using panels provided by Sunperfect Solar, Inc. and its proprietary Energy Yield Optimization™ service, which sets the standard for solar power plants today. The performance ratio – a measure of efficiency for converting the sun's radiation into electricity – of Premier Power constructed plants routinely exceeds the market's historical averages.

About Premier Power

Premier Power Renewable Energy, Inc. is a leading global provider of large and medium-scale solar power systems, delivering unmatched experience to commercial, governmental and utility customers globally. Premier Power designs, engineers and integrates the solar industry's leading products. Premier Power's technologies and services have enabled its customers to maximize clean energy output along with project savings.

Last Trade: 0.22 52 Week: 1.01 – 0.17 Market Cap: 6.45 Million

Unigene Announces Fourth Quarter and Full-Year 2011 Results

Unigene Laboratories, Inc. (OTCBB: UGNE), today announced financial results for the fourth quarter and full-year ended December 31, 2011. The Company highlighted key corporate accomplishments in 2011 and outlined its anticipated milestones for 2012.

Fourth Quarter and Full-Year 2011 Financial Summary

Unigene announced positive net income of $4.4 million or $0.05 per share for the three months ended December 31, 2011 compared to a net loss of $3.9 million or ($0.04) per share for the same period in 2010. This favorable change was mainly due to the termination of the Company’s oral PTH analog license agreement with GSK, whereby previously deferred milestone payments (in the aggregate amount of $7.7 million) were recognized as revenue. The Company reported a net loss of $17.9 million for the full-year ended December 31, 2011 or ($0.19) per share compared to a net loss of $27.9 million or ($0.30) per share for 2010.

Revenue for the three months ended December 31, 2011 was $12.5 million, compared to $2.9 million for the three months ended December 31, 2010. Revenue for the full-year ended December 31, 2011 was $20.5 million compared to $11.3 million for 2010.

Additional Financial Results & Notes

Revenue for the year ended December 31, 2011 increased $9.2 million, or 81%, to $20.5 million from $11.3 million in 2010. This favorable change was primarily due to an increase in licensing revenue of $9.0 million mainly resulting from the termination of the Company’s license agreement with GSK, whereby previously deferred upfront and milestone payments in the aggregate amount of $7.7 million were recognized as revenue. I

Unigene had operating income of $6.4 million for the three months ended December 31, 2011, an improvement of $9.1 million from the operating loss of $2.7 million for the three months ended December 31, 2010. Operating loss for the twelve months ended December 31, 2011 decreased approximately $6.8 million, or 66%, to $3.5 million from $10.3 million for the corresponding period in 2010.

Net loss for 2011 decreased approximately $10.0 million, or 36%, to $17.9 million from $27.9 million in 2010.

Cash and cash equivalents at December 31, 2011 totaled $4.7 million compared to $12.2 million at the same time point in 2010. Cash and cash equivalents at September 30, 2011 totaled $5.2 million. Based on the Company’s current projections, cash flow is expected to be sufficient to fund its business operations through the end of 2012.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence.

Last Trade: 0.50 52 Week: 1.42 – 0.37 Market Cap: 47.36 Million

Intellicheck Mobilisa Announces 2011 Fourth Quarter and Year End Financial Results

Intellicheck Mobilisa (NYSE Amex: IDN) has released its financial results for the fourth quarter and year ended December 31, 2011.

Revenues for the quarter ended December 31, 2011 decreased 6% to $2,868,031 compared to $3,046,567 in the same period of the previous year. Adjusted EBITDA was $283,835 for the fourth quarter of 2011 compared to $(253,795) for the fourth quarter of 2010. Net loss for the three months ended December 31, 2011 was $13,907 or $(0.00) per diluted share compared to a net loss of $641,844 or $(0.02) per diluted share for the three months ended December 31, 2010. The Company’s backlog, which represents non-cancelable sales orders for products not yet shipped and services to be performed, was approximately $2.8 million at December 31, 2011, compared to $2.8 million at December 31, 2010.

For the year ended December 31, 2011, revenues increased 2% to $12,484,331 compared to revenues of $12,291,551 reported in the same period of the prior year. Adjusted EBITDA for 2011 increased to $875,164 compared to $(938,934) in 2010. Net loss was $290,859 or $(0.01) per diluted share for the year ended December 31, 2011, compared to a net loss of $2,573,223 or $(0.10) for the year ended December 31, 2010.

About Intellicheck Mobilisa

Intellicheck Mobilisa (ICMOBIL) is a leading technology company that is engaged in developing and marketing wireless technology and identity systems for various applications, including mobile and handheld access control and security systems for the government, military and commercial markets. ICMOBIL’s products include the Fugitive Finder system, an advanced ID card access control product currently protecting approximately 100 military and federal locations

Last Trade: 1.129 52 Week: 1.40 – 0.81 Market Cap: 31.03 Million

Chembio Diagnostics Reports Fourth Quarter and 2011 Financial Results

Chembio Diagnostics, Inc. (PINKSHEETS: CEMI) (OTCQB: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the three and 12 months ended December 31, 2011, including record revenues and earnings for the year. The 2011 results reflect the reversal of $5.16 million in deferred tax asset valuation allowance previously recorded against its deferred tax assets, which resulted in a tax benefit increase to net income of that amount. The 2010 results include $1.47 million in Qualified Therapeutic Discovery Project grants ("QTDP") under Section 48D of the Internal Revenue Code, as enacted under the Patient Protection and Affordable Care Act of 2010. This amount was reflected as a reduction of R&D expenses.

Financial highlights for the fourth quarter of 2011 include the following (all comparisons are with the fourth quarter of 2010):

• Total revenues of $6.22 million, up 9.7% compared with $5.67 million

• Product sales of $5.91 million, up 14.1% compared with $5.18 million

• Operating Income of $551,000, down from $1.93 million. Operating income for 2010 includes the effect of QTDP grants of $1.47 million.

• Net income of $5.68 million or $0.09 per diluted share, up from net income of $1.88 million or $0.03 per diluted share. Net income includes the reversal of $5.16 million in deferred tax asset valuation allowance in 2011 and the effect of QTDP grants in 2010

Financial highlights for 2011 include the following (all comparisons are with 2010):

• Total revenues of $19.39 million, up 16.6% compared with $16.70 million

• Product sales of $17.42 million, up 28.9% compared with $13.52 million

• Operating Income of $1.09 million, down from $2.57 million. Operating income for 2010 includes the effect of QTDP grants of $1.47 million

• Net income of $6.21 million or $0.10 per diluted share, up from net income of $2.51 million or $0.04 per diluted share. Net income includes the reversal of $5.16 million in deferred tax asset valuation allowance in 2011 and the effect of QTDP grants in 2010

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $7 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere North America, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies.

Last Trade: 0.46 52 Week: 0.58 – 0.21 Market Cap: 29.12 Million

H2O Innovation Awarded CAD$2.8 Million in Contracts for Industrial and Municipal Water Treatment Systems

H2O Innovation Inc. ("H2O Innovation" or the "Company") (TSX VENTURE:HEO)(ALTERNEXT:MNEMO:ALHEO) announces today that it was recently awarded $2.8 million in new contracts. These new contracts will see H2O Innovation provide custom-built water treatment systems to industrial and municipal end-users in the United States and Canada. The contracts bring H2O Innovation's equipment order backlog to $28.6 million as of March 8, 2012.

The most significant contract announced today will see H2O Innovation design, fabricate, deliver and install a Bio-Brane™ membrane bio-reactor wastewater treatment and water reuse system to an industrial end-user active in the oil and gas sector in Northern Alberta. The aboveground steel package Bio-Brane™ system will be used to treat sanitary wastewater from the client's work camp. H2O Innovation's BioBrane™ technology is a high-efficiency IFAS MBR (integrated fixed-film activated sludge and membrane bioreactor) system used for municipal or industrial wastewater treatment and water reuse applications around the world.

Another contract will see H2O Innovation build and deliver a system to a municipal end-user, the City of Hillsboro, North Dakota, for which the Company will manufacture a nanofiltration/reverse osmosis membrane softening water treatment system for the production of drinking water.

About H 2 O Innovation

Building on 11 years of experience, H2O Innovation provides integrated technological water treatment solutions based on membrane filtration technology to municipal, energy & mining end-users. H2O Innovation designs state-of-the-art custom-built water treatment systems for the production of drinking water and industrial process water, the reclamation and reuse of water, and the treatment of wastewater, while providing a complete line of specialty chemicals and consumables for membrane filtration and reverse osmosis systems.

Last Trade: 0.225 52 Week: 0.52 – 0.21 Market Cap: 13.53 Million

Diversified Global Holdings Group Subsidiary Awarded $1.5 Million Construction Contract from $3.5 Million LOI With TZK Aerofuels

Diversified Global Holdings Group, Inc. (OTCBB:DGHG), an international holding company, announced today that its Russian construction subsidiary, SibTechServis-N (STSN), has been awarded a $1.5 million construction contract with TZK Aerofuels. As the exclusive contractor for Aerofuels in 2012, the Company announced in December 2011 a $3.5 million Letter of Intent (LOI) with Aerofuels. Work will include remodeling of aircraft hangars and offices as well as the construction of new hangars and offices at various Aerofuels locations throughout Russia.

TZK Aerofuels provides fuel supplies to 800 locations worldwide and provides jet fuels to more than 70 air carriers within the Russian Federation, such as Aeroflot, S7 Airlines, Vladivostok Avia, Tesis, Atlant-Soyuz, the Russian Emergency Response Ministry and the Russian Ministry of Defense. For more information, visit http://www.aerofuels.ru/eng/.

About SibTechServis-N

SibTechServis-N was founded in 2006 and is located in Novosibirsk, Russia. STSN currently performs general construction for commercial energy projects and municipality infrastructure such as roads and airport runways. For additional information visit http://sts.sfo.ru.

About TZK Aerofuels

In operation since 1999, TZK Aerofuels http://www.aerofuels.ru/eng/tzk_agit.php has on-going agreements with 17 Russian airports for into-plane fuelling of regular passenger & charter flights and cargo airlines.

About Diversified Global Holdings Group, Inc.

Diversified Global Holdings Group, Inc. is a holding company with strong subsidiaries worldwide. The Company has proven M&A expertise and intends to maintain its focus in three core divisions (construction, real estate development and business consulting), while expanding its operations in these sectors both through organic growth and acquisitions - primarily in emerging markets. For more information, visit www.diversifiedglobalholdings.com.

Last Trade: 0.53 52 Week: 7.28 – 0.35 Market Cap: 49.45 Million